Pharmaceuticals & Life Sciences

Merck Completes Acquisition of EyeBio

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has announced the completion of the acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck. EyeBio’s lead candidate, Restoret™ (EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site […]

Merck Completes Acquisition of EyeBio Read More »

Illumina Buys Fluent BioSciences to Better Speak the Language of Single-Cell Analysis

Despite letting go of Grail last month, Illumina isn’t shying away from M&A. The DNA sequencing giant has now acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research. Launched in 2018 with tech developed at the University of California, San Francisco, Fluent was previously backed by Illumina’s independent venture capital arm.

Illumina Buys Fluent BioSciences to Better Speak the Language of Single-Cell Analysis Read More »

Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis with the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26

Johnson & Johnson (NYSE: JNJ) announces that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024. NM26, which is ready to enter

Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis with the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 Read More »

Are ‘Next-Gen’ Biotech Acquirers Experiencing Their Moment?

Is it prime time for the “next-gen” biopharma acquirers? The headlines have flourished since April. Genmab and Ono Pharmaceutical made their first acquisitions. Vertex inked its largest M&A deal since its founding. Incyte went back to the acquisition well after a brief period on the sidelines. Biogen quickly returned to shopping mode after having just digested

Are ‘Next-Gen’ Biotech Acquirers Experiencing Their Moment? Read More »

Merck Animal Health Completes Acquisition of Elanco’s Aqua Business

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), has announced the completion of its acquisition of the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN). The completion of this acquisition bolsters Merck Animal Health’s position in

Merck Animal Health Completes Acquisition of Elanco’s Aqua Business Read More »

Scroll to Top